BGI, a leading global genomics organization headquartered in Shenzhen, announced it is expanding its international operations with the formation of a new division, BGI Groups USA, to be based in Seattle. BGI is engaged in scientific research, genomic sequencing, precision medicine, agriculture, bioinformatics and related technologies with a vision to use genomics to benefit humanity.
A BGI led team of researchers has sequenced the Ginkgo biloba genome and found it to be full of repeats, as well as gene clusters that may explain the tree’s remarkable resilience.
BGI and five British Columbia-based biomedical and healthcare organizations have allied on personalized medicine. The Canadian partners include Providence Health Care, St. Paul’s Foundation, the Vancouver Prostate Centre, Genome BC, and Deloitte. Together, the organizations will create “health centers of excellence” in Shenzen, China, where BGI is based, and Vancouver, British Columbia.
Official opening of the China National GeneBank (CNGB) marks a new phase in Chinese-International genomics collaboration, providing scientists from across the world with access to one of the world’s most comprehensive and sophisticated biorepositories, with the goal of enabling breakthroughs in human health research and contributing to global biodiversity conservation efforts.
BGI and the Centre for Social Evolution in Copenhagen (CSE) publish joint study in Nature Communications revealing the genetic changes that enabled fungus farming ants and their cultivars to be so successful. Read our press release or contact us to discover how we can help with your research project.
BGI, global leader in genomics research and clinical applications, is actively using functional studies data provided by biotech startup, Ranomics, for gene variant classification. Ranomics’ database oﬀers experimental data about genetic Variants of Unknown Significance (VUS), providing new insights into the function of VUS in model organisms.